NEW YORK (GenomeWeb) – Qiagen and Chinese in vitro diagnostics firm Maccura Biotechnology announced today that they have formed a joint venture focused on commercializing Qiagen's GeneReader next-generation sequencing system in China and developing gene panels for the Chinese market.

The JV, called Maqgen, will be based in Chengdu, Sichuan Province, and is owned 60 percent by Maccura and 40 percent by Qiagen. Thierry Bernard, senior VP and head of Qiagen's molecular diagnostics business area, said that Qiagen's stake could grow to 49 percent after three years.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.